Market Overview

Baird Comments On Achillion's Bullish Share Action

Share:

Baird analyst Brian Skorney reported on “increasingly bullish” share action of Achillion Pharmaceuticals (NASDAQ: ACHN) following SEC filing by Idenix Pharmaceuticals (NASDAQ: IDIX).

Skorney remarked that Achillion's stock action has been very bullish after the Idenix SEC filing showing that at least one bidder was “pushing $3 billion” as an offer. The analyst added that there are likely more “enthusiastic pharma bidders looking to acquire a nucleotide analog.”

Baird commented that the company is the “only game in town” with its nucleotide analogue roughly a half a year behind Idenix.

The analyst rates Achillion as Outperform with a $12.00 price target.

Shares of Achillion Pharmaceuticals closed at $8.08 on Thursday. The stock was last trading at $8.27, up 2.29 percent.

Latest Ratings for ACHN

DateFirmActionFromTo
Oct 2019SVB LeerinkDowngradesOutperformMarket Perform
May 2019BarclaysDowngradesEqual-WeightUnderweight
May 2018BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

 

Related Articles (ACHN)

View Comments and Join the Discussion!

Posted-In: Baird Brian SkorneyAnalyst Color Price Target Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com